CLVLY Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 21:25):

Stats
Tagesvolumen	502.00
Durchschnittsvolumen	4 112.00
Marktkapitalisierung	500.79M
Last Dividend	$0.0320 ( 2023-09-07 )
Next Dividend	$0 ( N/A )
P/E	27.01
ATR14	$0 (0.00%)

Clinuvel Pharmaceuticals Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Clinuvel Pharmaceuticals Finanzdaten

Annual	2023
Umsatz:	$78.32M
Bruttogewinn:	$50.59M (64.59 %)
EPS:	$0.620

FY	2023
Umsatz:	$78.32M
Bruttogewinn:	$50.59M (64.59 %)
EPS:	$0.620

FY	2022
Umsatz:	$65.72M
Bruttogewinn:	$46.62M (70.93 %)
EPS:	$0.420

FY	2021
Umsatz:	$47.98M
Bruttogewinn:	$43.26M (90.16 %)
EPS:	$0.502

Financial Reports:

No articles found.

Clinuvel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0270 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.0320 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Clinuvel Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.23 - Stable (24.67%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0140	2018-09-20
Last Dividend	$0.0320	2023-09-07
Next Dividend	$0	N/A
Payout Date	2023-10-02
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$0.126	--
Avg. Dividend % Per Year	0.00%	--
Score	3.05	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.23
Div. Directional Score	8.30	--

Next Divdend (Est)
(2024-07-01)

$0.0374 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.05

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
UEPEO	Ex Dividend Knight	2023-07-20	Quarterly	0.00%
JSAIY	Ex Dividend Junior	2023-06-08	Annually	0.00%
BKUTK	Ex Dividend Junior	2023-06-29	Semi-Annually	0.00%
RSTRF	Ex Dividend Knight	2023-09-19	Semi-Annually	0.00%
FAXRF	Ex Dividend Junior	2023-09-14	Quarterly	0.00%
WTBFA	Ex Dividend Junior	2023-09-07	Quarterly	0.00%
LTOUF	Ex Dividend Junior	2023-08-01	Annually	0.00%
CHEOY	Ex Dividend Knight	2023-09-15	Annually	0.00%
SNMCY	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
GLPEY	Ex Dividend Knight	2023-08-25	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.371	1.500	2.58	3.86	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.176	1.500	9.16	10.00	[0.1 - 1]
payoutRatioTTM	0.0819	-1.000	9.18	-9.18	[0 - 1]
currentRatioTTM	6.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.38	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.321	1.500	3.77	5.66	[0.2 - 2]
debtRatioTTM	0.00505	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.725	2.00	9.64	10.00	[0 - 20]
debtEquityRatioTTM	0.00598	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.483	1.000	2.33	2.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	39.55	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	25.13	1.000	7.56	0	[1 - 100]
returnOnEquityTTM	0.176	2.50	9.46	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.725	2.00	9.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.212	1.500	4.71	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
payoutRatioTTM	0.0819	1.500	9.18	-9.18	[0 - 1]
pegRatioTTM	0.271	1.500	-1.526	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.520	1.000	10.00	0	[0.1 - 0.5]
Total Score				6.23

Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.